Clinical approach to drug resistance interpretation: Expert advice

Current Opinion in HIV and AIDS

Volumn 2, Issue 2, 2007, Pages 145-149

  Clotet, Bonaventura ^a   Paredes, Roger ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Conference calls; Expert advice; Genotype; Phenotype; Resistance; Salvage therapy

Indexed keywords

ANTIRETROVIRUS AGENT;

DRUG BIOAVAILABILITY; DRUG EFFICACY; ENVIRONMENT; GENOTYPE; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; KNOWLEDGE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; THERAPY EFFECT; TREATMENT FAILURE; VIROLOGY;

EID: 34250618330     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32801470f6     Document Type: Review

References (22)

1. Palella FJ, Delaney KM, Moorman, et al., the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev 2004; 6:123-130.
3. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearence rate, infected cell lifetime, and viral generation time. Science 1996; 271:1582-1586.
4. Clotet B, Menéndez-Arias L, Schapiro JM, et al., editors. Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects, 6th ed. Barcelona, Spain: Fundació Lluita Contra la SIDA; 2006.
5. Conlon CP, Klenerman P, Edwards A, et al. Heterosexual transmission of HIV-1 variants associated with zidovudine resistance. J Infect Dis 1994; 169:411-415.
6. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with HIV-1: 2003 Recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2003; 37:113-128.
7. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046b Study Team for the Terry Beirn Community Programs for Clinical research on AIDS. AIDS 2000; 14:F83-F93.
8. Meynard J-L, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
9. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
10. Mazzotta F, Caputo SL, Torti C, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. J Acquir Immune Defic Syndr 2003; 32:268-280.
11. Perez-Elias MJ, Garcia-Arata I, Muñoz V, et al., for the Realvirfen Study Group. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther 2003; 8:577-584.
12. Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance. J Acquir Immune Defic Syndr 2005; 38:553-559. This study did not demonstrate an added value of phenotypic resistance testing in conjunction with genotypic resistance testing in patients with limited therapeutic options.
13. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Topics HIV Med 2006; 14:125-130.
14. Stanford University. HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu/. [Accessed November 2006]
15. Badri SM, Adeyemi OM, Max BE, et al. How does expert advice impact genotype resistance testing in clinical practice? Clin Infect Dis 2003; 37:708-713.
16. Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antiviral Ther 2000; 5:65-70.
17. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-2199.
18. Palella F, Armon C, Chmiel J, et al. Enhanced survival associated with the use of HIV susceptibility testing among HAART-experienced patients in the HIV outpatient study (HOPS). In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA; 5-8 February 2006. Abstract 654.
19. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356. In this analysis the emergence of any resistance after first-line HAART was associated with increased mortality (hazard ratio 1.75, 95% confidence interval 1.27-2.43). Moreover, resistance to NNRTIs was associated with a greater risk of subsequent death than was the emergence of protease inhibitor resistance.
20. Vingerhoets J, Janssen K, Welkenhuysen-Gybels J, et al. Impact of baseline K103N or Y181C on the virological response to the NNRTI TMC-125: analysis of study TMC125-C223. In: XVth International HIV Drug Resistance Workshop. Sitges, Spain; 13-17 June 2006. Abstract 17.
21. Harrigan PC, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005; 191:1325-1330. The results of this study suggested that analysis of a combined historical genotype rather than of a cross-sectional genotype may lead to more accurate estimates of antiretroviral drug resistance in individual patients and in patient populations.
22. Llibre JM, López-Blázquez R, Galindo MJ, et al. Benefit of call conference expert advice discussion in treatment-experienced patients with virologic failure. In: 4th European HIV Drug Resistance Workshop. Monaco; 29-31 March 2006. Abstract 65.